Quarterly report pursuant to Section 13 or 15(d)

Organization, Plan of Business Operations (Details)

v3.22.2.2
Organization, Plan of Business Operations (Details)
Jul. 25, 2022
Vote
shares
Jun. 30, 2022
USD ($)
shares
May 11, 2022
USD ($)
Mar. 31, 2022
USD ($)
Feb. 15, 2022
Vote
Dec. 31, 2021
USD ($)
shares
Jun. 30, 2021
USD ($)
Mar. 31, 2021
USD ($)
Dec. 31, 2020
USD ($)
Stockholders' equity | $   $ 598,000   $ 1,159,000   $ 3,451,000 $ 642,000 $ 1,475,000 $ 2,359,000
Reduction in common shares authorized | shares   50,000,000       50,000,000      
Voting power 99                
Percentage of voting power of the company's capital stock held by holders, signed the written consent 73.00%                
Accumulated deficit | $   $ 80,464,000       $ 76,999,000      
Cash and cash equivalents | $   $ 890,000       $ 3,763,000      
Number of no votes | Vote         14        
Minimum                  
Reverse stock split ratio 10                
Reduction in common shares authorized | shares 20,000,000                
Maximum                  
Reverse stock split ratio 20                
Reduction in common shares authorized | shares 50,000,000                
Invagen Pharmaceuticals Inc                  
Proceeds from equity financing | $     $ 100            
Invagen Pharmaceuticals Inc                  
Number of yes votes | Vote         8        
Common stock                  
Number of shares held by holders of company's stock, signed the written consent | shares 9,423,429                
Number of votes per share | Vote 1                
Preferred Stock                  
Number of shares held by holders of company's stock, signed the written consent | shares 250,000                
Voting power 1.1                
Fortress | Contribution Agreement                  
Ownership percentage transferred     100.00%            
Fortress | Contribution Agreement | Minimum                  
Proceeds from equity financing | $     $ 7,500,000